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Abstract
Purpose Multiple interventions have been developed aiming to reduce time to antibiotics (TTA) in patients with fever and
neutropenia (FN) following chemotherapy for cancer. We evaluated their effect to reduce TTA and their impact on important
clinical outcomes in a systematic review.
Methods The search covered seven databases. Biases and quality of studies were assessed with the Risk of Bias in Non-
randomized Studies of Interventions (ROBINS-I) tool. Interventions could be implemented in any setting and performed by
any person included in the FN management. Absolute change of TTA was the primary outcome. Registration: PROSPERO
(CRD42018092948).
Results Six thousand two hundred ninety-six titles and abstracts were screened, 177 studies were retrieved and 30 studies were
included. Risk of bias was moderate to serious in 28 studies and low in two studies. All but one study reported a reduction of TTA
after the intervention. Various types of interventions were implemented; theymost commonly aimed at professionals. Most of the
studies made more than one single intervention.
Conclusion This review may help centers to identify their specific sources of delay and barriers to change and to define what
intervention may be the best to apply. This review supports the assertion that TTA can be considered a measure of quality of care,
emphasizes the importance of education and training, and describes the very different interventions which have effectively
reduced TTA.
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Background
In patients with cancer, fever in chemotherapy-induced severe
neutropenia (FN) is the most frequent potentially lethal compli-
cation of chemotherapy for cancer [1]. When absolute neutrophil
count drops below 0.5 × 109/L the risk of life-threatening bacte-
rial infection increases [2]. Prompt empirical therapy with broad-
spectrum antibiotics is standard of care and lethality is below 1%
in pediatric patients [3, 4] and approximately 10% in adult pa-
tients [5], but still FN remains the leading cause of emergency
hospitalization. Time to antibiotics (TTA) usually refers to the
amount of time passed from arrival at the hospital to administra-
tion of antibiotics, and despite inconsistent evidence about the
association of TTA and clinical outcomes, guidelines [6–8] and
experts insist that timely and appropriate antibiotic administration
is essential for adequate patient care. TTA < 60 min is even used
as a measure of quality of care [9]. Presuming the beneficial
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effect on patient-important outcomes, several groups have
attempted to reduce TTA in patients with FN by implementing
specific interventions in emergency departments (ED) and oncol-
ogy wards. These interventions have never been summarized, so
this systematic review aimed to identify and synthesize informa-
tion on interventions performed, their effect to reduce TTA, and
the potential use of these approaches.
Methods
The protocol for this review was registered on PROSPERO
(CRD42018092948) prior to commencing the work and has
been published [10]. Simultaneously with this systematic re-
view, we collected information about the association between
TTA and clinical outcomes in patients with FN under chemo-
therapy for cancer, published separately [11]. This section is
an adapted version of the methods reported there.
Electronic searches of MEDLINE, MEDLINE In-Process &
Other Non-Indexed Citations, EMBASE, CINAHL, CDSR,
CENTRAL, and LILACS were performed on May 9th, 2018.
The search was updated on April 5th, 2019. The search strategy
included the Medical Subject Heading terms and text words to
identify fever and neutropenia and the intervention of treatment
with antibiotics. Antibiotics were additionally searched by
groups and names of antibiotic drugs (e.g., penicillin, beta-
lactams, quinolones).
In EMBASE search, “time”was added as a required search
factor to narrow the results. Studies from 1997 onward were
eligible, no language restrictions were applied. Pilot searching
took place before the actual search and found all five previous
identified studies [12–16]. The full search strategies are pro-
vided with the protocol publication [10]. Manual searches of
references and forward citation searching of included articles
was conducted. Authors of relevant studies and experts within
the field were contacted to seek further studies.
Study selection
Inclusion and exclusion criteria were defined a priori. Studies
investigating any intervention or combination of interventions
attempting to reduce TTA in adult or pediatric patients with
cancer, or after hematopoietic stem cell transplantation, and
FN were included. Interventions could be implemented in in-
patient or outpatient settings, performed by any person included
in the FN management. All kind of studies, except case reports
and those presented only as abstract or posters, were eligible.
OutcomesAbsolute change of TTAwas the primary outcome.
Secondary outcomes were TTA measurements other than ab-
solute, safety, and treatment adequacy. Safety was defined as
death, admission to intensive care unit (ICU), and/or severe
sepsis (including septic shock); treatment adequacy was
defined as relapse of primary infection, persistence of fever,
and/or recurrence of fever without a new infection. Additional
clinical outcomes as microbiologically defined infections,
days of fever, length of hospital stay (LOS), modification of
antibiotics, new infections, and composite outcomes that each
individual study selected were recorded.
Exclusion criteria Studies were excluded if (1) they were not
specific to cancer or did not report on this subgroup separately
(mixed populations were permitted if > 50% population were di-
agnosed with cancer/hematopoietic stem cell transplantation); (2)
they did not report TTA; (3) they did not have data of an accurate
comparator group, defined as cared for in the same way, in the
same setting, and with the same treatment regimens, except of the
intervention studied. The comparison group could be of the same
cohort and could be observed simultaneously or successively.
ScreeningOne reviewer (CK) screened the title and abstract of
all studies for inclusion. A second reviewer (CS) independent-
ly screened 60% of the titles and abstracts. The kappa statistic
for agreement was calculated and showed good agreement
between reviewers (k = 0.91, 95% confidence interval (CI)
0.87 to 0.94). Full text was obtained for all potential articles
of interest. All full texts were assessed for eligibility by two
reviewers (CK and CS; k = 0.79, 95% CI 0.69 to 0.89).
Fourteen studies were referred to a third reviewer (RSP),
where 11 were excluded.
Data extraction and risk of bias assessment
Data extraction and risk of bias assessment was done by one
reviewer (CK) and independently checked by a second
(RAA). Discrepancies were resolved by consensus.
Intervention characteristics were collected according to the
Cochrane Effective Practice and Organization of Care
Review Group (EPOC) data collection checklist [17]. Risk
of bias was assessed using the Risk of Bias in Non-
randomized Studies of Interventions (ROBINS-I) tool [18] at
the level of the individual study. All articles were included in
the review irrespective of the risk of bias.
Statistical methods
Due to heterogeneity within the implemented interventions,
study sites, and participants, meta-analysis was not undertaken
and a narrative synthesis was performed. To visually display the
results of the primary outcome, reduction of TTA, a forest plot
was drawn including all studies for which mean and standard
deviation (SD) were reported or could be estimated. In studies
only reporting median, interquartile range (IQR) or 95% confi-
dence intervals of the mean, and SDwere estimated assuming a
normal distribution (median ¼ mean; SD ¼ IQR= 1:35; SD ¼
95%CI=3:92 ﬃﬃﬃnp ) [19].
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Results
Overview
Titles and abstracts from 6296 studies were assessed and 177
full-text articles retrieved. A flow diagram of the study selec-
tion is provided in Fig. 1. Thirty studies were included, thir-
teen in adult [12, 20–31], and seventeen in pediatric patients
[16, 32–47], including a total of 1891 and 6820 FN episodes,
respectively. Two-third of the studies were undertaken in the
USA (n = 20; 67%). There were four multicenter studies (in-
cluded number of centers, 2 to 4) and the vast majority of
studies were undertaken in academic hospitals (n = 25;
83%). No randomized or quasi-randomized trials were identi-
fied by the searches. Before and after studies were the most
commonly used design (n = 29; 97%), in which TTA was
evaluated at baseline and after the implementation of an inter-
vention. Various studies collected TTA atmultiple time points,
but none of them performed an interrupted time series analy-
sis. The remaining study was a retrospective cohort study [26].
Characteristics of included studies are given in Table 1.
Most of the interventions were implemented at EDs
(26; 87%). Fever was defined within a temperature
range of ≥ 38.0 to ≥ 38.5 °C. Seventeen studies defined
neutropenia as an absolute neutrophil count (ANC) < 0.5 ×
109/L and/or < 1.0 × 109/L expected to decrease. Four studies
defined neutropenia as ANC < 1.0 × 109/L. Other definitions
were leucocyte count ≤ 4.0 × 109/L or < 1.0 × 109/L,
ANC < 0.2 × 109/L, or < 0.58 × 109/L and expected to
decrease. TTA was measured from triage or arrival at
the hospital to first dose of antibiotics in the majority
of studies (n = 26; 87%). One study with adult patients
started measurement of time at fever detection [30], one study
defined TTA as time from initial provider evaluation to intra-
venous antibiotic administration, [44], and the third study
started measurement at ICU admission [32]. In one study, a
definition was lacking [36]. The definitions used per study are
displayed in Online Resource 1, Table 1.
Risk of bias
Study quality and risk of bias assessment identified a moder-
ate or serious risk for bias in all but two of the included studies
(Table 1, for full assessment: Online Resource 1, Table 2).
Potential confounders for TTA were set at FN diagnosis, lo-
calization of presentation (ED versus oncology ward versus
oncology outpatient unit), high patient volumes, presence of
central line, and knowledge of staff about an ongoing study
(Hawthorne effect) [32]. Additionally, risk status of patients,
initial illness severity, time of presentation, and administration
route of antibiotics were identified as possible but measurable
confounders in almost all studies.
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Interventions
Various types of interventions were implemented, most of the
studies made more than one single intervention. Among the
thirty studies, the most common group of intervention targeted
professionals. They consisted of distribution of FN-Alert
cards to patients, skills training, education for staff, and edu-
cational updates or feedbacks. Twenty-two studies imple-
mented guidelines, algorithms, or checklists for FN treatment.
The collected interventions are summarized in Online
Resource 1, Table 3. No study used regulatory or financial
interventions.
The studies were indexed to setting, type of intervention,
education of staff, implementation of guidelines, algorithms or
checklists, and whether they had a follow-up or not (Table 2).
Online Resource 1, Table 3 gives an overview of the applied
interventions. The number of intervention events varied from
1 to 7, and duration of intervention was from one single inter-
vention point up to 3 years. Interventions were provided and
delivered by local physicians, nurses, pharmacist, laboratory
staff, and employees from administration and hospital bed
control. One study was supported by hospital quality improve-
ment experts [46] and one by members of the Information
Technology department [40]. Unit of allocation and analysis
were always the individual patients, and the purpose of rec-
ommendation was always appropriate management of these
patients.
Targeted behaviors were diagnosis (n = 13), test ordering
(n = 6), procedures (n = 19), prescribing (n = 12), general
management of a problem (n = 19), patient education/advice
(n = 11), and communication between professionals (n = 8).
To address them, various formats were used like interpersonal,
paper, visual, computer, paging system, and phones.
Several articles identified sources of delays and barriers to
improve TTA; these are presented separately between adult
and pediatric studies in Table 4.
Reduction of TTA
All 28 studies that compared TTA before and after an inter-
vention reported a reduction in TTA after the intervention
(Table 2). Only one of these studies [12], performed in adults,
reports a statistically non-significant result, even when TTA
declined from a mean of 244 to 195 min (p = 0.09). This study
was judged at moderate risk for bias. One study displayed
TTA only graphically [36], but equally shows a reduction of
TTA. The remaining retrospective cohort study [26] compared
TTA in four different hospitals while the interventionwas only
implemented in one. Likewise, this study showed a significant
shorter TTA in the intervention hospital (3.9 versus 4.9 h,
p = 0.02).
TTA is reported as continuous variable in all but two stud-
ies [31, 41]. These specific studies only report an increase inTa
bl
e
1
(c
on
tin
ue
d)
St
ud
y
Y
ea
r
C
ou
nt
ry
Si
ng
le
or
D
at
a
co
lle
ct
io
n
In
te
rv
en
tio
n
de
si
gn
de
fi
ne
d
by
ea
ch
st
ud
y
au
th
or
s
S
et
tin
g
F
N ep
is
od
es
A
ss
es
se
d
pu
b
(l
an
gu
ag
e)
m
ul
tis
ite
E
D
O
ut
pa
tie
nt
un
it
In
pa
tie
nt
un
it
(p
at
ie
nt
s)
ri
sk
of
bi
as
R
et
ro
sp
ec
tiv
e
an
d
pr
os
pe
ct
iv
e
Sp
en
ce
r
et
al
.[
43
]
20
17
U
SA
(E
)
M
ul
tis
ite
R
et
ro
sp
ec
tiv
e
Q
ua
lit
y
im
pr
ov
em
en
tp
ro
je
ct
Y
es
N
o
N
o
10
32
(1
03
2)
M
od
er
at
e
V
an
de
rw
ay
et
al
.[
44
]
20
17
U
SA
(E
)
Si
ng
le
si
te
R
et
ro
sp
ec
tiv
e
an
d
pr
os
pe
ct
iv
e
Q
ua
lit
y
im
pr
ov
em
en
tp
ro
je
ct
N
o
Y
es
N
o
25
(2
5)
M
od
er
at
e
V
ed
ie
ta
l.
[4
5]
20
15
A
us
tr
al
ia
(E
)
M
ul
tis
ite
R
et
ro
sp
ec
tiv
e
A
lg
or
ith
m
-b
as
ed
ap
pr
oa
ch
Y
es
N
o
N
o
89
(8
9)
M
od
er
at
e
V
ol
pe
et
al
.[
46
]
20
12
U
SA
(E
)
Si
ng
le
si
te
R
et
ro
sp
ec
tiv
e
Q
ua
lit
y
im
pr
ov
em
en
tp
ro
je
ct
,p
la
n-
do
-
st
ud
y
ac
tc
yc
le
Y
es
N
o
N
o
36
5
(3
65
)
L
ow
Y
os
hi
da
et
al
.[
47
]
20
18
U
SA
(E
)
Si
ng
le
si
te
P
ro
sp
ec
tiv
e
2-
ph
as
e
qu
al
ity
im
pr
ov
em
en
tp
ro
je
ct
Y
es
N
o
N
o
71
8
(3
27
)
M
od
er
at
e
E
,E
ng
lis
h;
E
D
,e
m
er
ge
nc
y
de
pa
rt
m
en
t;
F
N
,f
ev
er
an
d
ne
ut
ro
pe
ni
a;
IC
U
,i
nt
en
si
ve
ca
re
un
it;
N
A
,n
ot
av
ai
la
bl
e;
pu
b,
pu
bl
is
he
d
Support Care Cancer
Ta
bl
e
2
In
te
rv
en
tio
n
an
d
tim
e
to
an
tib
io
tic
s
re
du
ct
io
n
in
th
e
in
cl
ud
ed
st
ud
ie
s
S
tu
dy
Ty
pe
of
in
te
rv
en
tio
n
S
ta
ff
ed
uc
at
io
n
C
he
ck
lis
t/
gu
id
el
in
es
F
ol
lo
w
-u
p
T
TA
be
fo
re
in
te
rv
en
tio
n
(m
ea
n)
T
TA
af
te
r
in
te
rv
en
tio
n
(m
ea
n)
A
bs
ol
ut
e
T
TA
re
du
ct
io
n
%
T
TA
re
du
ct
io
n
%
w
ith
T
TA
≤
60
m
in
be
fo
re
/a
ft
er
Pr
of
es
si
on
al
O
rg
an
iz
at
io
na
l
Pr
ov
id
er
P
at
ie
nt
St
ru
ct
ur
al
B
al
tic
et
al
.[
20
]
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
N
o
18
8
m
in
64
m
in
12
4
m
in
66
%
N
A
B
es
te
ta
l.
[2
1]
(1
)
B
es
te
ta
l.
[2
1]
(2
)
Y
es
N
o
N
o
Y
es
Y
es
Y
es
N
o
18
8
m
in
11
5
m
in
73
m
in
38
%
N
A
Y
es
N
o
N
o
Y
es
Y
es
Y
es
N
o
22
8
m
in
16
3
m
in
65
m
in
29
%
D
an
g
et
al
.[
22
]
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
N
o
10
0
m
in
27
m
in
73
m
in
73
%
31
%
/9
5.
5%
H
aw
le
y
et
al
.[
23
]
(1
)
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
N
o
13
8
m
in
91
.6
m
in
46
.4
m
in
34
%
N
A
H
aw
le
y
et
al
.[
23
]
(2
)
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
N
o
70
m
in
52
.6
m
in
17
.4
m
in
25
%
N
A
K
ap
il
et
al
.[
12
]
Y
es
N
o
N
o
N
o
N
o
N
o
N
o
24
4
m
in
19
5
m
in
49
m
in
20
%
N
A
K
en
g
et
al
.[
24
]
Y
es
N
o
N
o
Y
es
Y
es
Y
es
N
o
23
5
m
in
*
81
m
in
*
15
4
m
in
66
%
1%
/3
2%
K
o
et
al
.[
25
]
N
o
N
o
N
o
Y
es
N
A
Y
es
N
o
30
0
m
in
47
m
in
25
3
m
in
84
%
0
to
86
%
L
im
et
al
.[
26
]
Y
es
N
o
N
o
N
o
Y
es
Y
es
N
o
4.
9
h*
3.
9
h*
1
h
20
%
N
A
L
im
et
al
.[
27
]
Y
es
Y
es
N
o
Y
es
Y
es
Y
es
N
o
26
1
m
in
*
95
m
in
*
16
6
m
in
64
%
N
A
M
ei
se
nb
er
g
et
al
.[
28
]
Y
es
N
o
Y
es
Y
es
Y
es
Y
es
N
o
25
2
m
in
*
11
7
m
in
*
13
5
m
in
54
%
N
A
S
al
te
r
et
al
.[
29
]
N
o
Y
es
N
o
Y
es
N
o
Y
es
N
o
3.
8
h*
3.
45
h*
0.
35
h
9%
N
A
V
an
V
lie
te
ta
l.
[3
0]
N
o
Y
es
N
o
Y
es
N
o
N
o
Y
es
75
.1
m
in
32
.0
m
in
43
.1
m
in
57
%
N
A
W
el
ls
et
al
.[
31
]
Y
es
Y
es
N
o
Y
es
Y
es
Y
es
N
o
N
A
N
A
N
A
N
A
31
%
/7
9%
A
m
ad
o
et
al
.[
32
]
N
o
N
o
N
o
Y
es
N
o
N
o
N
o
16
4
m
in
55
m
in
10
9
m
in
66
%
0%
/5
2%
B
en
ne
r
et
al
.[
33
]
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
20
7
m
in
*
88
.5
m
in
*
11
8.
5
m
in
57
%
0.
9%
/6
7%
C
as
h
et
al
.[
34
]
Y
es
Y
es
N
o
Y
es
Y
es
Y
es
N
o
15
4
m
in
*
95
m
in
*
59
m
in
38
%
2%
/3
%
C
oh
en
et
al
.[
35
]
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
96
.9
m
in
69
.5
m
in
27
.4
m
in
28
%
35
%
/5
1.
4%
C
or
ey
et
al
.[
36
]
Y
es
Y
es
N
o
Y
es
Y
es
N
o
Y
es
T
TA
on
ly
gr
ap
hi
ca
lly
re
po
rt
ed
N
A
N
A
N
A
D
ob
ra
sz
et
al
.[
37
]
(1
)
D
ob
ra
sz
et
al
.[
37
]
(2
)
Y
es
Y
es
N
o
Y
es
Y
es
Y
es
Y
es
89
m
in
44
m
in
45
m
in
51
%
N
A
Y
es
Y
es
N
o
Y
es
Y
es
Y
es
Y
es
11
0
m
in
61
m
in
49
m
in
45
%
N
A
E
m
er
so
n
et
al
.[
38
]
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
N
o
11
6
m
in
55
m
in
61
m
in
53
%
N
A
L
am
bl
e
et
al
.[
39
]
Y
es
N
o
N
o
Y
es
Y
es
Y
es
Y
es
11
5
m
in
*
60
m
in
*
55
m
in
48
%
12
%
/4
6%
L
uk
es
et
al
.[
40
]
Y
es
Y
es
N
o
Y
es
Y
es
N
o
Y
es
10
8
m
in
*
47
m
in
*
61
m
in
56
%
17
%
/8
3%
M
on
ro
e
et
al
.[
41
]
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
N
o
N
A
N
A
N
A
N
A
30
%
/8
0.
4%
Pa
ka
ka
sa
m
a
et
al
.[
42
]
Y
es
Y
es
N
o
Y
es
Y
es
Y
es
N
o
18
0
m
in
*
75
m
in
*
10
5
m
in
58
%
N
A
S
al
st
ro
m
et
al
.[
16
]
Y
es
N
o
Y
es
Y
es
Y
es
N
o
Y
es
16
4
m
in
45
.2
m
in
11
9
m
in
73
%
19
to
74
%
S
pe
nc
er
et
al
.[
43
]
(1
)
S
pe
nc
er
et
al
.[
43
]
(2
)
S
pe
nc
er
et
al
.[
43
]
(3
)
Y
es
Y
es
Y
es
Y
es
N
A
Y
es
Y
es
11
8.
5
m
in
*
57
m
in
*
61
.5
m
in
52
%
N
A
Y
es
Y
es
Y
es
Y
es
N
A
Y
es
Y
es
16
3
m
in
*
97
.5
m
in
*
65
.6
m
in
40
%
N
A
Y
es
Y
es
Y
es
Y
es
N
A
Y
es
Y
es
18
8
m
in
*
11
1.
5
m
in
*
76
.5
m
in
41
%
N
A
V
an
de
rw
ay
et
al
.[
44
]
Y
es
Y
es
N
o
Y
es
Y
es
Y
es
N
o
79
.6
m
in
41
.2
m
in
38
.4
m
in
48
%
N
A
V
ed
ie
ta
l.
[4
5]
(1
)
Y
es
Y
es
N
o
Y
es
Y
es
Y
es
Y
es
14
8
m
in
76
m
in
72
m
in
49
%
0
to
35
%
Support Care Cancer
percentage of patients treated within 60min, as it was reported
by several other studies, in addition to continuous TTA
(Table 2). The relative reduction of TTA is displayed in
Fig. 2 for studies reporting mean and SD or when those pa-
rameters could be estimated.
Clinical outcomes
Safety Most studies were underpowered to address safety
(mortality, ICU admission, or occurrence of severe sepsis).
Number of deaths was reported by eleven studies [16, 24,
25, 31, 33, 35, 36, 39, 42, 43, 46], with a median mortality
of 0% (maximum 39%) before and median mortality of 0%
(maximum 6%) after the intervention. No significant differ-
ences of mortality before and after intervention were detected
in seven of these 11 studies. One study only reported the
overall number of deaths [43]. One study [25] found an in-
crease in mortality from 0 (0/19 episodes) to 6% (3/50 epi-
sodes; p < 0.05), but these are equally low numbers of deaths
and no significant difference was found when death was in-
cluded into a composite outcome together with serious medi-
cal complications (1/19 versus 7/50; p = 0.45). A decrease in
mortality was shown in two studies [31, 42]. For adult pa-
tients, Wells et al. [31] report a high mortality of 39% (14 of
36 episodes) before and a mortality of 0% (0 of 79 episodes)
after their intervention. Their intervention increased the per-
centage of patients treated within 60 min from 14 to 79%, but
no absolute times are reported. For pediatric patients,
Pakakasama et al. [42] reports a significant reduction in mor-
tality from 6.5 (9 of 138 episodes) before to 0% (0 of 170
episodes; p = 0.001) after the implementation of guidelines.
In their study, ICU admission and septic shock were as well
significantly reduced after the implementation, 9.4 to 2.9%
(p = 0.016) and 10.9 to 3.5% (p = 0.011), respectively.
Numbers of ICU admissions were reported by eight studies
[24, 25, 33, 35, 36, 39, 42, 46], with a median of 5% (maxi-
mum 9%) before and a median of 1.3% (maximum 7%) after
the intervention. Only one study [16] found a difference in
need for ICU admission before and after the intervention
(34% versus 12.8%; p < 0.05). This study describes extending
the study period when the results were not significant, without
describing the number or nature of the interim analyses. Sepsis
was additionally analyzed by one adult study [25], where al-
most all patients before (84%) and after the intervention (90%)
were diagnosed with sepsis.
Treatment adequacy No study reported relapses of primary
infection, persistence of fever for more than 5 days, or recur-
rence of fever without a new infection.
Additional outcomes Numbers of patients with an identified
source of infection/bacteremia were comparable within the
investigated groups before and after the intervention in allTa
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Table 3 Sources of delays (number of studies reporting) in adult and pediatric patients
Adult patients Pediatric patients
Staff related Staff related
• Lack of awareness of potential risk/knowledge about FN (5)
• FN patients not recognized (3)
• Difficulties in obtaining central venous access (3)
• Long waiting time for phlebotomist to set up the intravenous line (1)
• Long turn-around time from setting of the prescription by
pharmacist to drug dispensing (1)
• Antibiotics not scheduled as urgency by pharmacist (1)
• Lack of staff (1)
• Long waiting time for initial physician assessment (3)
• Delay related to waiting for a second medical review (1)
• Physician trainees involved in care (1)
• Communication issues (1)
• Lack of awareness of potential risk/knowledge about FN (2)
• FN patients not recognized (1)
• Difficulties in obtaining central venous access due to lack of
training/technical difficulties (4)
• No physician available (for examination or order for antibiotics) (4)
• Lack of expertise, fear of treating oncology patients (3)
• Communication with specialist/staff (3)
Patient related Patient related
• Lack of knowledge of patients (1) • Difficulties in obtaining central venous access due to inadequate
topical analgesia (3)
• Difficulties in obtaining central venous access due to parents
requesting specific nurses/other expectations (3)
Procedure related Procedure related
• Lack of a triage system (1)
• Unavailability of laboratory results (4)
• Missing FN protocols (1)
• Absence of order set (2)
• Large number of patients, multiple concomitant admissions (1)
• Antibiotics not available at emergency (1)
• Delayed administration of antibiotics due to structural issues (3)
(after transfer to inpatient unit, only on next drug round)
• Lack of access to important patient information (1)
• Day of the week (1)
• Unawareness of patient arrival (1)
• Difficulties in obtaining central venous access due to lack of
equipment (1)
• Unavailability of laboratory results (6)
• Antibiotics not available at emergency (5)
• Two separate policies for BMT and non-BMT patients (1)
• ED crowding/Competing unwell patients (1)
• No exam/infusion room available, room not prepared (2)
• Guidelines not accessible (1)
• Patient information cannot be entered into the computer system
until the patient’s arrival on the unit (1)
• Lack of access to important patient information (1)
BMT, bone marrow transplant; ED, emergency department; FN, fever and neutropenia
Table 4 Barriers to change (number of studies reporting) in adult and pediatric patients
Adult patients Pediatric patients
Staff related Staff related
• Disempowerment of clinicians diagnosing and caring for the patient (1)
• Lack of understanding, ignorance or stubbornness, concerns with
lack of autonomy (physician) (2)
• Lack of order set compliance, low guideline usage (2)
• Lack of communication between professionals (1)
• Lack of ongoing education (1)
• ED overcrowding, (not enough staff) (1)
• Persisting mind-set to confirm neutropenia before antibiotics (1)
• False sense of security: “just another FN patient” (1)
• Lack of knowledge due to rotating residents/medical students (1)
• Education difficulties due to part-time and rotate shifts (2)
• Lack of guideline compliance (3)
• Forgetting the availability of standard dose of antibiotics (1)
• Overwhelming workload, priorities for other patients (2)
Patient related Patient related
• Fever alert card unsuitable for some patients (to big, neglect the
replacement of a full card) (1)
• Inadequate consultations/intolerance of patients (1)
• Patient/parents preferences of staff for central venous access (2)
Procedure related Procedure related
• Lack of communication of order-set-availability (1) • Institution not used to standardized processes (1)
• State regulation (protocol cannot be initiated before an attending
physician assumes care for a patient) (1)
• Already close to target before intervention (1)
ED, emergency department; FN, fever and neutropenia
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studies that analyzed these [16, 24, 27, 39, 42]. Likewise none
of three studies with data about duration of fever found a
significant difference within the groups [16, 25, 32].
For length of hospital stay (LOS), five studies [24, 25, 27,
29, 33] did not find a significant difference before and after the
intervention. In one of those studies [24], LOS was reduced
after an intervention when compared with a historical cohort
in a multivariable analysis that adjusted for age, disease type,
MASCC risk index, prophylactic antibiotics, central line, and
ANC, but not in univariate analysis. Only the pediatric study
of Pakakasama et al. [42], who described improved safety,
showed that LOS decreased significantly after the interven-
tion. Median LOS was 5 days (range, 1–30 days) in the 170
episodes of the intervention group, whereas it was 7 days
(range, 1–170 days) in the 138 episodes of the control group
(p = 0.001). In one study [21], LOS was shorter before (mean
11.33 days; n = 30) than after the intervention (mean
17.43 days; n = 23). The authors explain this finding by low
number of patients and outliers due to unequal groups.
Modification of antibiotics and new infections were not re-
ported by any study.
Subgroup analyses
Only the planned subgroup analyses between pediatric and
adult patients were possible to be undertaken. The main find-
ing was different sources of delays in these two groups
(Table 3). Regardless of these different barriers, the durations
and reductions were broadly similar: TTA before an interven-
tion varied between an average (median or mean) of 70–
300 min in adult studies and 79.6–221 min in pediatric
studies. After an intervention, adult studies showed TTAs be-
tween 27 and 234 min and pediatric studies between 41.2–
111.5 min. Reduction of the average TTAwas between 17.8–
253 min (or 9–84%) in adult and 18–156 min (or 22–73%) in
pediatric studies.
Discussion
TTA can be effectively reduced by very different interventions
in a wide range of practice settings in both pediatric and adult
patients with fever and neutropenia during chemotherapy for
cancer. Most of the identified interventions were aimed at
modifying the behavior of professionals and implemented at
EDs; implementation of guidelines or a checklist were the
most often used strategies. Although it is reasonable to assume
that publication bias strongly influences this result if only
effective interventions are reported, this systematic review
helps to identify possible sources of delays and summarizes
different strategies to address them.
Guidelines or checklists are useful to address patient-, pro-
cedure-, and staff-related factors at once and they were used
by 77% of the included studies. Whereas patient- and
procedure-related factors may be more difficult to address
otherwise, staff-related factors can be resolved by regular ed-
ucation and training. Unsurprisingly, staff-related factors were
also a common reason for delays of TTA and professional
interventions were very often used. A systematic review eval-
uating effective knowledge translation strategies in cancer
[48] found that the most promising interventions were profes-
sional ones, like educational outreach, audits, and feedbacks.
Fig. 2 Relative reduction in TTA of studies reporting mean and standard deviation or when those parameters could be estimated
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In line with these results, our systematic review supports the
fact that education and training remain core elements for a
successful reduction in TTA. One study showed a reduction
in median TTA about 1 h, only by informing staff about al-
ready existing guidelines [26]. Unfortunately staff-related is-
sues were also the most often identified barriers to change
(Table 4).
Published interventions without professional approaches
were all organizational: standing orders allowing nurses to
administer antibiotics before calling a physician [29, 30],
making antibiotics rapidly available [32], and implementation
of a treatment protocol without emphasizing staff education
[25]. Among them was the study with the largest TTA reduc-
tion [25], with a reduction of mean TTA by 253 min, keeping
in mind that this study also reports the longest TTA before the
organizational change (mean 300 min).
Presentation at the ED has been identified as a reason for
longer TTA [15, 49] and more frequent adverse events [14].
This matches our finding that 26 (87%) of the identified stud-
ies were undertaken in EDs. High workload due to high pa-
tient volumes and lack of training in care of oncology patients
may explain this. Three included studies [26, 34, 47] men-
tioned ED overcrowding and lack of staff as a barrier to
changes; these are factors difficult to address by physicians
but should be acknowledged by institutions, where identified.
A study from Canada [50] identified age > 60 years and
lack of caregiver as a risk factor for delayed TTA. In our
review, only three studies identified patient-related factors as
barriers to change; this may reflect the largely positive input of
patients or lack of specific research into these issues.
There were several challenges to summarizing the primary
data sources. Through differences in the definitions of key
study variables, it was not possible to identify specific inter-
ventions that are more likely to be effective than others. The
studies were undertaken in different countries and their results
must be interpreted in the context of different healthcare pro-
visions. Additionally, the interventions were uneven with re-
spect to type of intervention, number and duration of interven-
tions, what person delivered the intervention, target of behav-
ior, and format used. Because often a number of changes were
instituted simultaneously, it is not possible to determine the
impact of any single change.
Almost all studies were before and after studies. The iden-
tified Hawthorne effect (knowledge of staff about an ongoing
study) may have an important influence and therefore follow-
up assessments after the intervention should be undertaken to
see whether the improvements are sustainable. Outcomes,
such as TTA, may change over time for reasons unrelated to
the implemented strategy. If repeated observations before and
after an intervention are available, the more robust interrupted
time series analysis should be conducted [51]. Assessment of
clinical outcomes was limited due to low numbers.
Additionally, inclusion of patients at different risk for medical
complications creates a triage bias, i.e., faster treatment of
patients with worse clinical condition [11] and may therefore
mask an effect of shorter TTA in the included studies.
The key strength of this manuscript lies in its thorough
application of systematic review methodology. It thus pro-
vides the most complete summary of interventions aiming to
reduce TTA in patients with FN during chemotherapy for
cancer. Additionally, it provides a clearly arranged list of
sources of delays and barriers to change TTA, and the under-
taken risk of bias assessment helps to judge the validity of the
results in TTA reduction.
Conclusion
TTA can be effectively reduced by very different interven-
tions; however, the direct impact of a shorter TTA on clinical
outcomes could not be determined. Education and training
were identified as core elements to successfully reduce TTA
and remain essential to improve quality of care. Some centers
already defined TTA ≤ 60 min as a valid measure of quality of
care [9, 24], and although the clinical implication of a shorter
TTA is not yet clear [11], our results support the assertion that
TTA can be considered a measure of quality of care. This
systematic review can be used by care teams as a checklist
to identify sources of delays and to evaluate what may be the
most important and effective intervention to implement in
their specific center to reduce TTA.
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